bridgebio

hope through
rigorous science

Corporate Presentation

November/December 2024

Forward Looking Statements and Disclaimer

The presentation contains forward-looking statements. Statements made or presented may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believe,” “anticipate,” “plan,” “expect,” “intend,” “will,” “may,” “goal,” “potential,” “should,” “could,” “aim,” “estimate,” “predict,” “continue” and similar expressions or the negative of these terms or other comparable terminology are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements, including express and implied statements relating to the FDA approval of Attruby (acoramidis), the clinical, therapeutic and market potential of our clinical development programs and our pipeline, our speed of creating new and meaningful drugs and related impact on patients, the efficiency of our engine to rapidly and efficiently deliver medicines, our value creation potential for patients, the potential market sizes and opportunities, the safety, efficacy and mechanisms of our newly FDA-approved Attruby (acoramidis) and other later-stage products including infigratinib and encaleret, our financial position, the potency and safety of our product candidates, the potential benefits of our product candidates, the potential for greater patient access to medications, the affordability and availability of insurance coverage of our medications, and the timing and expectations regarding results of our various clinical trials, reflect our current views about our plans, intentions, expectations and strategies, which are based on the information currently available to us and on assumptions we have made. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about the Company, including, without limitation, risks inherent in developing therapeutic products, and those risks and uncertainties described under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) and in subsequent filings made by the Company with the SEC, which are available on the SEC’s website at www.sec.gov. In light of these risks and uncertainties, many of which are beyond the Company’s control, the events or circumstances referred to in the forward-looking statements, express or implied, may not occur. The actual results may vary from the anticipated results and the variations may be material. You are cautioned not to place undue reliance on these forward-looking statements, which speak to the Company’s current beliefs and expectations only as of the date of the presentation. Except as required by law, the Company disclaims any intention or responsibility for updating or revising any forward-looking statements made or presented at the presentation in the event of new information, future developments or otherwise. No representation is made as to the safety or effectiveness of the product candidates for the therapeutic use for which such product candidates are being studied.

Certain information communicated at the presentation may relate to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company’s own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of the presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, certain information to be communicated at the presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, such research has not been verified by any independent source.

Such information is provided as of the date of the presentation and is subject to change without notice. The Company has not verified, and will not verify, any part of this presentation, and the Company makes no representation or warranty, express or implied, as to the accuracy or completeness of the information to be communicated at the presentation or as to the existence, substance or materiality of any information omitted from the presentation at the presentation. The Company disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this document or the related presentation and such liability is expressly disclaimed.

Attruby™ (acoramidis) 356 mg tablet

...is now FDA approved

Indicated for the treatment of adult patients with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization

Our objective function

Patient impact…

Objective: max $\int_0^t \sum_{Drugs\ i=1}^{N} \frac{\Delta QALY\ (i)}{patient} * patients\ (i)$

BridgeBio maximizes **the speed** of creating
as many new and meaningful drugs
that have a **profound impact** on as
many patients as possible

…through sustainable value creation

Each project must be:

- Based on beautiful science with a high probability of technical success (POTS)
- NPV positive (driven by ROIC, g, WACC)

Inspiration – "Strategy: A History" by Lawrence Freedman

BridgeBio is a new type of biopharmaceutical company

From:	*To:*
Slow and bureaucratic decision making	Rapid and decentralized decision making
Expensive platforms with long lead times before proof-of-concept data	Assets selected to target genetic diseases at their source
High fixed costs	Variablized and flexible costs
Limited sources of capital	Strategic toolkit of financing options at the levels of the portfolio and affiliate companies
Incentives at the portfolio level	Incentives at the level of each asset to preserve focus at the level of biology

Inspiration – "Financing drug discovery for orphan diseases" by Andrew Lo

The right approach: decentralized R&D, centralized infrastructure

Build **"minimum viable companies"** to de-risk programs as quickly and efficiently as possible

Leverage **hyper-experienced R&D practitioners** who are focused on the science of each individual program

Provide investors with **increased choice in where to participate** in our ecosystem

Build **central infrastructure** for functions with economies of scale, such as commercial

Leverage **seasoned company builders** and **centralized capital allocators** to take the best possible shots on goal

Provide investors with a **de-risked portfolio of assets**; enable access to low-cost debt

Inspiration – "Scale" by Geoffrey West

The right space: capitalizing on a scientific revolution to treat a massive unmet need for genetic diseases

Genetics

Macromolecules

Clinical Diagnosis

Therapeutic Modalities

Regulatory

nature medicine — **Genetic association analysis of 77,539 genomes reveals rare disease etiologies**

Science JOURNALS AAAS — **Accurate proteome-wide missense variant effect prediction with AlphaMissense**

nature reviews genetics — **The expanding diagnostic toolbox for rare genetic diseases**

nature biotechnology — **New drug approvals reached an all-time high in 2023, with five gene therapies, the first CRISPR–Cas9-edited therapy and a disease-modifying Alzheimer's drug.**

FDA — **FDA issues final guidance on rare disease drug development**

There are **10,000+ counted rare diseases** affecting **450 million+ people globally**



This leaves **hundreds of millions of people** across **6,500 diseases** with known molecular cause who are **anxiously waiting** for therapies

Greene, D. et al. Nat Med. 2023; Cheng, J. et al. Science. 2023; Kernohan, K.D., Boycott, K.M. Nat Rev Genet. 2024; Senior, M. Nat Biotechnol. 2024; FDA; NIH; RareX; Science; Nature; NEJM; NHGRI

Our leadership team has world-renowned drug hunters and operators

Neil Kumar, PhD
Founder and Chief Executive Officer
THIRD ROCK VENTURES · MyoKardia

Thomas Trimarchi, PhD
President &
Chief Operating Officer
REGENERON · Goldman Sachs

Brian Stephenson, PhD, CFA
Chief Financial Officer
LEERINK · CAPITAL IP

Uma Sinha, PhD
Chief Scientific Officer
GBT · PORTOLA PHARMACEUTICALS

Robert Zamboni, PhD
Chemistry
MERCK FROSST

Jonathan Fox, MD, PhD
Chief Medical Officer,
Cardiorenal
MyoKardia · AstraZeneca

Ananth Sridhar
Chief Operating Officer,
Cardiorenal
REGENERON · Genentech

Christine Siu
Chief Executive Officer,
Muscular Dystrophy
BLUEFIELD PROJECT · GBT

Justin To
Chief Executive Officer,
Skeletal Dysplasias
flatiron · McKinsey & Company

Eric David, MD, JD
Chief Executive Officer,
Gene Therapy
organovo · McKinsey & Company

Charles Homcy, MD
Founder and Chairman of
Pharmaceuticals
MyoKardia · GBT

Frank McCormick, PhD
Founder and Chairman of
Oncology
ONYX PHARMACEUTICALS · UCSF

Richard Scheller, PhD
Chairman of R&D
Genentech · 23andMe

Len Post, PhD
Advisor
BIOMARIN · LEAD THERAPEUTICS

Phil Reilly, MD, JD
Advisor
THIRD ROCK VENTURES · bluebirdbio

We have built a sustainable, high velocity engine to deliver medicines



Attruby™ (acoramidis) 356 mg tablet

Nulibry® (fosdenopterin) for injection

TRUSELTIQ™ (infigratinib) capsules

3 approved medicines

> 2,000 patients in trials

> 30 trials
> 30 countries
> 500 sites

3 ongoing pivotal trials

> 70 papers published

> 35 academic partnerships

18 INDs created

< $10M and **< 3 yrs** to IND

A pipeline of products that sing across the BridgeBio ecosystem

Program	Indication	Pre-clinical	Phase 1	Phase 2	Phase 3	Approved	Patients (US + EU)	Market Opportunity
Attruby (acoramidis)	Transthyretin Amyloidosis (ATTR-CM)					✓	500,000+	$15-$20B
Nulibry (fosdenopterin)	Molybdenum Cofactor Deficiency (MoCD) Type A					✓	<100	Partnered
Truseltiq (infigratinib)	Cholangiocarcinoma					✓	37,000	Partnered
Infigratinib (low-dose)	Achondroplasia (ACH)						55,000	$2B+
	Hypochondroplasia (HCH)						55,000	$2B+
Encaleret	Autosomal Dominant Hypocalcemia Type 1 (ADH1)						20-25,000	$1B+
	Post-Surgical Hypoparathyroidism (PSH)						200,000	$1B+
BBP-418	Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)						7,000	$1B+
BBP-812	Canavan Disease				Phase 1/2 Pivotal		1,000	TBD

… along with meaningful equity and collaboration with two clinical-stage sister companies, BridgeBio Oncology Therapeutics and GondolaBio

Three Phase 3 clinical trial readouts in the next year

	Recent Achievements	2025
Infigratinib	Published Phase 2 study results in the New England Journal of Medicine	Topline data from PROPEL 3 pivotal study and continued execution in hypochondroplasia
Encaleret	Published Phase 2B study results in the New England Journal of Medicine	Topline data from CALIBRATE pivotal study and continued execution in pediatric ADH1 and post-surgical hypoparathyroidism
BBP-418	Completed enrollment of Phase 3 FORTIFY study in patients with LGMD2I/R9	Topline data from FORTIFY study interim analysis, supporting opportunity to pursue accelerated approval in US

Attruby
Now Approved





Attruby is now FDA Approved – Key Highlights

Attruby™ (acoramidis) 356 mg tablet

- First and only approved product with a label specifying **near-complete stabilization** of TTR
- Effect seen **as early as 3 months** – the most rapid benefit seen in any Phase 3 study of ATTR-CM to date
- **42% reduction** in composite of all-cause mortality and recurrent cardiovascular-related hospitalization events at Month 30
- **50% reduction** in the cumulative frequency of cardiovascular-related hospitalization events at Month 30

Our responsibility to patients spans beyond R&D – we are committed to ensuring the best access and affordability of any ATTR-CM medicine

Dedicated patient support team

Insurance navigation and support

Ensuring easy and fast access:
Medicine **shipped directly** to patient within **48 hours** of coverage approval

The least expensive ATTR treatment:
$0 OOP for many patients
max $167 per month for Medicare Part D

Drug available direct to patients' home or through institutions

Easily accessible Copay and Patient Assistance Program

Our support programs are laser focused on providing access to patients

forgingbridges™

1. **High-Touch Patient Support** — Dedicated and fully integrated HUB focused on rare disease

2. **Accessible Copay & PAP** — PAP and copay programs offer greater eligibility and support while minimizing patient burden

3. **Simple HUB Enrollment** — HUB enrollment is fast and straightforward

Our commercial infrastructure is deployed across the US to ensure full provider coverage

ATTR-CM Prescriber Market



8K+ prescribing HCPs, ~100 COEs hold significant influence with prescribers & communicate overall product value

BridgeBio Coverage

- Dedicated commercial & US-field-based team with singular focus on serving patients with ATTR-CM
- Salesforce is built to adequately cover every HCP and institution prescribing in ATTR-CM
- Robust segmentation to maximize effectiveness

IQVIA Inc.; Definitive Healthcare, LLC; CareSet Systems, Inc.

ATTR-CM is a multi-billion-dollar market primed for continued expansion

Global annual ATTR market sales[1]



Drivers of market growth include:

- Increased global adoption of **non-invasive diagnostic tools**
- **Established international market familiarity** with oral TTR stabilizers
- Tailwinds from the **Inflation Reduction Act** anticipated to reduce patient out-of-pocket expenditure in US
- **Durable market growth** with tafamidis polymorph patent protection through 2035[3]

[1]ATTR market includes all approved drugs for ATTR-PN and ATTR-CM. 2024 sales annualized as of Q2 2024.
[2]Consensus estimates of $15B-$20B ATTR market.
[3]Orange Book.

New demand study shows significant Attruby market potential vs. partial stabilizer and partial knockdown

Surveyed HCPs expect 30 - 40%+ peak market share for Attruby

Attruby Market Share as % of Future Competitive Market

(August 2024 Research)



- Survey of 200 HCPs with a history of ATTR-CM prescribing in Rx data
- Included competitive profiles of stabilizer and knockdown products
- Conducted by third-party consulting firm in August 2024, post competitive data release

HCP sentiment towards Attruby is positive

> *Acoramidis showed dramatic reduction in cardiovascular hospitalizations, and improvement in patient QoL."*
>
> HCP - Northeast

> *There is a mortality benefit and there are also quality of life benefits. It is an oral medication, so that will be well-liked by patients."*
>
> HCP - West

> *Very impressive treatment effect and best data to date on what happens in a contemporary ATTR-CM population."*
>
> HCP - Central

Note: Stated share adjusted for historical performance of demand study market research on new product launches.
BridgeBio Market Research (N=200), Advisory board, IQVIA LAAD data set

Our Attruby team has experienced industry leaders who have built and launched blockbuster drugs

Matt Outten
Chief Commercial Officer

- Broad commercial leadership expertise with success across multiple competitive markets
- Led $5B+ portfolio, 12 FDA approvals spanning 6 disease states and 7 indications (IMBRUVICA, Pharmacyclics)
- Commercial lead on $21B pharma M&A deal

Julie Everett
Chief Business Officer

- Successfully led cross-functional teams through multiple rare disease launches, including VOXZOGO and PALYNZIQ (BioMarin)
- Led commercial strategy and execution across ~$1B portfolio
- ~Decade of strategy consulting leadership focused on launch excellence and lifecycle maximization (Trinity)

John Whang
Chief Medical Affairs Officer

- Orchestrated multiple successful launches with pioneering therapies in competitive segments – STELARA (Janssen), REPATHA (Amgen), and CAMZYOS (BMS)
- 8+ launches as strategy consultant (McKinsey)
- Demonstrated strategic innovation (Heartline Study – J&J / Apple collab) and consistently built outstanding organizations

Ana Merz
VP, Sales

Launched IMBRUVICA ($5B+, 12 FDA approvals, 6 disease states, 7 indications in 10 years) and EPKINLY (3L+ DLBCL)

Sean Doherty
SVP, Marketing

Broad global sales and marketing launch experience including in rare, infectious, and auto-immune diseases

Scott Collins
SVP, Market Access

Extensive market access experience with consistent coverage across rare disease and oncology, leading large field-based access teams

Hudson Boyer
VP, Commercial Analytics & Ops

Launches in rare disease, hematology, and immunology; strategy consulting and equity analyst background

Liz Arnold
Head of Commercial Strategy

Multiple global launches, expertise in strategy, consulting, and marketing across rare disease, hematology, and OTC

Recently published data from the OLE further support Attruby's statistically significant benefit on ACM and ACM/Recurrent CVH



Attruby resulted in a **statistically significant** ACM and ACM/Recurrent CVH relative risk reduction at **both Month 36 and Month 42**

Source: Judge et al., Circ 2024. [1]Relative Risk Reduction based on percent of participants with ACM event at M30 and M36. [2]Relative Risk Reduction is calculated by (1-Relative Risk Ratio from the negative binomial regression analysis) x 100%. Note: Study limitations include lack of a true control treatment arm, and the exclusion of participants who elected not to enroll in the OLE due to desire to receive SOC.

BridgeBio is committed to advancing Attruby's scientific narrative to ensure as many appropriate patients as possible can benefit



Multi-prong data generation plan in place to solidify Attruby's differentiated clinical profile

Infigratinib

Achondroplasia is a large, proven commercial market annualizing to ~$750M today with substantial remaining treatable pool

Addressable patients by indication in US/EU[1]

(current population eligible for treatment)



Annualized achondroplasia product sales[2]

($M WW, annualized by quarter)



[1]CDC birth estimates; EU Eurostats birth estimates; Foreman, et al. Am J Med Genet. 2020.; Bober, et al. Gene Reviews. 2020.; Wenger, et al. Gene Reviews. 2020.; Al-Namman, et al. J Oral Biol Craniofac Res. 2019. [2]Achondroplasia market includes all approved drugs.

Infigratinib is a best-in-class FGFR3 inhibitor that targets achondroplasia and hypochondroplasia at their source

Mechanism



FGFR3 acts as a "molecular brake" on chondrocyte proliferation and hypertrophy; **in ACH or HCH, this brake is stuck** due to gain-of-function mutations resulting in shortened bones

Infigratinib "releases" the brake, potentially resuming normal chondrocyte function, allowing for restoration of bone growth

Design Principles

Maximize efficacy by targeting disease at the source

For all the manifestations of ACH and HCH, not just height, which matter for families and physicians

Demonstrate safety with low dosing

Avoiding hypotension & injection site reactions with no hyperphosphatemia, ocular effects or VEGFR3 off-target effects

Avoid injections and provide an oral option

For children and families, to reduce burden and pain of treatment

At 18 months, infigratinib has shown persistent improvement in AHV and body segmentation, along with a favorable safety profile

Mean change from baseline in annualized height velocity (AHV)



At each timepoint, infigratinib change from baseline AHV is higher than that reported by any other treatment option

At the highest dose, there were no SAEs, most TEAEs were of grade 1 severity, and none were assessed as related to study drug

Upper body to lower body segment ratio (Lower value means improved proportionality)



Infigratinib shows statistically significant proportionality improvements after 18 months

This has potential for a meaningful effect on body proportionality, and if maintained, can be associated with functionality

Encaleret

ADH1 is a serious and rare genetic condition for which there are no indicated therapies and diagnosis rates are low

12K ADH1 Carriers
~12K carriers of ADH1 causing variants in the US based on 4 population databases[1-2]

9K Treatable
73% of patients with ADH1 are symptomatic[3]

3K – 5K Currently Addressable
40-60% of symptomatic ADH1 patients are diagnosed today, anticipate increase



An analogous ADH1 market is XLH

	XLH	ADH1
Prevalence (US)	12K[5]	12K
Disease burden	Hypophosphatemia	Acute hypocalcemia risk, long-term hypercalciuria risk
Standard of care	Vitamin D, daily phosphate	Vitamin D, daily calcium
Registrational endpoint	Serum phosphate	Blood and urine calcium
Projected peak year sales	$2B+[6]	$1B+

Population prevalence estimates in literature[1-2]



[1]Dershem, et al. Amer Jour of Hum Genetics. 2020. [2]Data analyzed from the gnomAD, TopMed, and UK Biobank databases as of 2022. [3]Roszko, et al. JBMR. 2022. [4]US population estimated as 328M. [5]Company Presentation. [6]Evaluate Pharma. XLH = x-linked hypophosphatemia.

Encaleret is a first-in-class, disease-modifying therapy that targets the underlying disease mechanism of ADH1

Mechanism

Normal CaSR senses and regulates serum Ca levels to maintain homeostasis

Encaleret is a **CaSR antagonist** designed to decrease the sensitivity of CaSRs to extracellular calcium



ADH1 CaSR is overly sensitive to extracellular calcium



CaSR sensitivity restored in the presence of encaleret

Overactive CaSR causes dysregulation of calcium homeostasis, **encaleret** has the potential to normalize PTH, serum Ca, and urine Ca levels

Restore *PTH to the normal range*

Restore *serum calcium to the normal range*

Decrease *urine calcium to the normal range*

Design Principles

First and only investigational treatment directly targeting ADH1 at its source

Potential to restore physiologic mineral homeostasis that is disrupted by CaSR oversensitivity

Address common symptomology

Designed to normalize PTH, serum Ca, and urine Ca levels, potentially resolving key symptoms

Convenient oral dosing

First targeted treatment for ADH1 in a convenient form for patients and families

CaSR = Calcium Sensing Receptor; Ca = Calcium; PTH = Parathyroid Hormone.

Phase 2B results demonstrated rapid and sustained normalization of serum Ca, urine Ca, and serum PTH, without need for dose escalation

Mean responses through 18 months of treatment (N=13)



Participants with blood Ca and urine Ca in the target range



Encaleret normalized mean blood Ca, PTH, and urine Ca in participants with ADH1 over an 18-month period representing a meaningful improvement over SoC

Gafni R., et al., NEJM, 2023; 389:1245-1247. Gafni R., et al., Jour Endo Soc., 2023; 7(Suppl 1). Data reported as mean+SD. Values below limit of assay quantitation recorded as "0". Gray shading reflects normal range. Solid line for urine Ca reflects upper limit for men and dashed line reflects upper limit for women. Values shown for weeks 0, 8, 16, and 24 are pre-encaleret. ** p-value < 0.01 Month 18 compared to Baseline.

BBP-418

LGMD2I/R9 is a progressive neuromuscular disease with high unmet need, representing a >$1B market opportunity in the US and EU

Addressable patients by indication



Unmet need

- LGMD2I/R9 is an inherited neuromuscular disorder characterized by lower-limb weakness and loss of ambulation as well as respiratory decline and cardiac dysfunction
- No approved disease modifying agents for LGMD2I/R9
- Current standard of care is aimed at symptom management and includes physical therapy, steroids, and pain management
- Standard of care does not prevent continuous and progressive decline in LGMD2I/R9 patients

Market opportunity $1B+

[1]Liu, et al. Genetics in Medicine. 2019. [2]Includes all patients with potentially treatable mutations in FKRP, FKTN, and ISPD.

BBP-418 is a first-in-class, disease-modifying therapy with potential to be the first approved therapy for LGMD2I/R9

Mechanism

FKRP glycosylates alpha-dystroglycan (αDG), stabilizing muscle cells by binding extracellular ligands to act as a "shock absorber" for muscle fibers

Partial loss of function in FKRP results in dysfunctional, hypo-glycosylated αDG in muscle cells, increasing cell susceptibility to damage

Supply supraphysiological levels of synthesized, pharmaceutical grade ribitol upstream aiming to drive residual activity of mutant FKRP enzyme and increase αDG glycosylation levels



BBP-418 drives potential partial restoration of glycosylation of αDG

FKRP mutations prevent addition of CDP-ribitol to αDG, limiting function as a "shock absorber"

Design Principles

Provide first disease-modifying therapy

For patients with LGMD2I/R9 and potentially applicable for other α-dystroglycanopathies

Avoid safety concerns with FKRP modulation

Avoid off-target effects using a synthesized version of an endogenous compound with an encouraging safety profile

Convenient oral medicine

To reduce burden for patients and avoid safety concerns

Significant increases in glycosylated αDG in muscle and stabilization of ambulatory measures were observed in a Phase 2 study of BBP-418

Increase in glycosylated αDG in muscle observed post dosing with BBP-418 (median ± 95% CI)



Median (%)	16.5	39.4	39.7	44.3	5.9	9.5	10.4	25.7
N	8	8	7	6	6	5	6	1

Patient samples were interpolated to standard curve to determine % of normal glycosylation of αDG
+ 3 mo = Part 1, 90-day, +6 mo = Part 2, Month 3, + 15 mo = Part 3, Month 9
Median and 10–90% percentile are shown, Wilcoxon test was used to determine significance
MLB-01-003 Listing 16.4.1 and 16.1.4.2

Change from baseline in 10-meter walk test (m/s)



Blue line denotes natural history; red line denotes on-treatment data from Ph. 2 study.
Stabilization of 100-meter timed test and NSAD was also observed at 21 mo.
MLB-01-001 Listing 16.2.1 and MLB-01-003 Listing 16.2.1

BBP-812

Canavan disease is a severe, fatal, and ultra-rare neurodegenerative pediatric disease with no approved therapies

Unmet need

- Canavan is an ultra-rare neurodegenerative disease with ~1,000 patients across the US and EU
- Canavan is usually fatal within the first two decades of life, and >25% of patients die by the age of 10 years[1]
- Children with Canavan exhibit global and severe cognitive, motor, and language impairment, missing or regressing on most developmental milestones
- They require around the clock care – they cannot hold their heads up, sit, crawl, walk, are generally unable to speak, and suffer from seizures and spasticity
- There are no therapies available for Canavan disease

[1]Bley A, et al. Orphanet J Rare Dis. 2021 PMID: 34011350

BBP-812 is a first-in-class, disease-modifying therapy that targets Canavan disease directly at its source

Mechanism



BBP-812 is an AAV9 gene therapy which directly replaces the mutated ASPA gene that causes Canavan disease

Design Principles

Provide first disease-modifying therapy

Target the condition directly at the source, utilize single registrational study & biomarker for accelerated approval

Provide therapy with known safety profile

Leverage safety profile from approved AAV9 gene therapy (Zolgensma)

Avoid invasive neurosurgery

Provide a less invasive IV treatment option to minimize burden for patients and their caregivers

Significant, sustained reductions in NAA levels and improvement in motor function after 12-months of BBP-812 dosing in Phase 1/2 study

Urine N-acetylaspartic acid (NAA) levels



- BBP-812 reduces urine NAA from levels associated with typical Canavan disease to levels associated with mild disease
- Preliminary high-dose data suggest higher BBP-812 doses further reduce urine NAA levels

Gross Motor Function Measure (GMFM-88) Trajectory Analysis



- Trajectory analysis shows clear separation in GMFM-88 Total Score between individuals dosed with BBP-812 in treatment study (CVN-102, in red) vs. individuals in the natural history study (shown in gray).

Preliminary data on file shown; n=10.

About Attruby and BridgeBio

About Attruby™ (acoramidis)

Attruby is the only near-complete (≥90%) stabilizer of Transthyretin (TTR) approved in the U.S. for the treatment of adult patients with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization. Attruby was generally well-tolerated. The most common side effects were mild and included diarrhea and abdominal pain that were resolved without drug discontinuation. BridgeBio offers an extensive suite of programs to help patients access our medicines. Visit Attruby.com for more information, including full Prescribing Information.

About BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio's pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com.